PRODUCT INFORMATION



SB 202190

Item No. 10010399

CAS Registry No.:	152121-30-7	\sim
Formal Name:	4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-	N N
	imidazol-2-yl]-phenol	
MF:	C ₂₀ H ₁₄ FN ₃ O	Ń,
FW:	331.3	,>→(\)→_он
Purity:	≥98%	
UV/Vis.:	λ _{max} : 202, 295 nm	
Supplied as:	A crystalline solid	
Storage:	-20°C	F
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SB 202190 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB 202190 in the solvent of choice. SB 202190 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of SB 202190 in these solvents is approximately 0.25, 16, and 10 mg/ml, respectively.

SB 202190 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB 202190 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. SB 202190 has a solubility of approximately 0.14 mg/ml in a 1:6 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SB 202190 is a selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC₅₀ values of 50 and 100 nM, respectively.^{1,2} When tested at 10 μM, SB 202190 has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs).² Pyridinyl imidazole inhibitors, including this compound, directly bind p38 MAP kinases in the ATP binding pocket.³ Recently, SB 202190 has been used to elucidate the roles of p38 MAP kinases in inflammatory cytokine expression, nicotine-induced receptor expression, and HIV-mediated depressive disorder.4-6

References

- 1. Jiang, Y., Chen, C., Li, Z., et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38β). J. Biol. Chem. 271(30), 17920-17926 (1996).
- 2. Davies, S.P., Reddy, H., Caivano, M., et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(1), 95-105 (2000).
- 3. Fox, T., Coll, J.T., Xie, X., et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7(11), 2249-2255 (1998).
- 4. Fu, X., Lawson, M.A., Kelley, K.W., et al. HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner. J. Neuroinflammation 8(88), 1-12 (2011).
- 5. Riis, J.L., Johansen, C., Vestergaard, C., et al. CCL27 expression is regulated by both p38 MAPK and ΙΚΚβ signalling pathways. Cytokine 56(3), 699-707 (2011).
- 6. Röthig, A., Schreckenberg, R., Weber, K., et al. Effects of nicotine on PTHrP and PTHrP receptor expression in rat coronary endothelial cells. Cell Physiol. Biochem. 29(3-4), 485-492 (2012).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/29/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM